For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 12-Week Interim AnalysisEdwards K.R.a · Hershey L.b · Wray L.b · Bednarczyk E.M.c · Lichter D.b · Farlow M.d · Johnson S.e
aAlzheimer’s Diagnostic and Treatment Center, Neurological Research Center, Bennington, Vt., and Harvard Medical School, Boston, Mass.; bBuffalo Veterans Affairs Hospital, Department of Neurology; cUniversity at Buffalo, Department of Nuclear Medicine, Buffalo, N.Y.; dDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Ind.; eDepartment of Mathematics, Williams College, Williamstown, Mass., USA
Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy analyses were performed on data from 25 patients. Scores on the Neuropsychiatric Inventory (NPI-12) improved (decreased) by 7.52 points over the 12 weeks (marginally significant, p = 0.061). NPI-12 scores decreased by half in 12 of the 25 patients. Highly significant improvement was observed in scores on the NPI-4 subscale (delusions, hallucinations, apathy, and depression: p = 0.003). Scores on the Clinician’s Global Impression of Change (CGIC) improved by 0.95 points (significant, p = 0.02). Improvements also were found in secondary efficacy variables, including cognitive, functional, activities of daily living, sleep and confusion assessments. Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms. Adverse events generally were transient and of mild-to-moderate intensity. Two of the 25 patients discontinued galantamine because of nausea and anorexia. One serious adverse event was recorded, but it was judged to be unrelated to the study medication.
© 2004 S. Karger AG, Basel